History of Peptide Regulation: From Discovery to the 2026 Regulatory Landscape

The regulatory history of peptides is inseparable from the history of peptide science itself. As researchers identified new peptide structures and their biological functions, regulators adapted frameworks originally designed for small-molecule drugs to cover an expanding universe of biologically active compounds. The result is a regulatory patchwork that reflects decades of ad hoc decisions as much as coherent policy design. Understanding this history helps explain why the current landscape is as complex as it is.

1920s–1950s: The Insulin Era and the Birth of Peptide Medicine

The history of regulated peptide use begins with insulin. Frederick Banting and Charles Best's isolation of insulin in 1921 and its first clinical use in 1922 established that peptide compounds could serve as transformative medicines. By the late 1920s, commercial insulin production was underway, with Eli Lilly and Novo Nordisk becoming early manufacturers.

Regulatory oversight of insulin grew alongside its commercial scale. The US Congress passed the Food, Drug, and Cosmetic Act in 1938 following the sulfanilamide disaster, which required drugs to be demonstrated safe before sale. Insulin was subject to this framework from the outset, and its potency standardization was among the first regulatory actions applied to a biological medicine.

The 1940s and 1950s saw the first isolation and characterization of several peptide hormones: oxytocin (1950, Vincent du Vigneaud), ACTH/corticotropin, vasopressin, and glucagon (1955). These were quickly developed into regulated medicines—prescription biologics subject to the same FDA framework as insulin.

Regulatory lesson from this era: Peptides that became commercially important as medicines integrated into formal regulatory frameworks quickly. The complexity of the modern regulatory landscape stems largely from the explosion of research peptides that do not (yet) have commercial pharmaceutical sponsors pushing them through the approval process.

1960s–1980s: Growth Hormone and the Anabolic Concern

Human Growth Hormone (HGH) was first isolated and characterized in the late 1950s and early 1960s. Initial medical use relied on pituitary-extracted GH—a supply-limited, expensive product used only for severe pediatric GH deficiency. The Pituitary Program administered by the NIH in the US was the primary access point for HGH through the 1970s.

In 1985, the US national HGH program was suspended when it was linked to fatal Creutzfeldt-Jakob disease transmission from contaminated pituitary material. The same year, Genentech received FDA approval for the first recombinant human growth hormone (Protropin), manufactured through genetic engineering. This marked a watershed in peptide regulation: recombinant technology could produce pure, safe peptide hormones at commercial scale.

Through the 1970s and early 1980s, GH abuse in sports began emerging—particularly in bodybuilding and strength sports. By the time the Anabolic Steroid Control Act of 1990 placed anabolic steroids in Schedule III of the Controlled Substances Act, GH itself had already attracted regulatory attention as a performance-enhancing drug. The FDA tightened GH prescribing rules in 1996, limiting its use to specific approved indications and requiring more specific diagnostic criteria.

Regulatory lesson from this era: Performance-enhancing potential drives regulatory tightening. GH's trajectory—from rare medical treatment to controlled prescription drug to anti-doping target—previewed what would happen to GH secretagogues decades later.

1990s: Recombinant Peptides, Sermorelin, and the First Compounding Wave

The 1990s saw both the approval of new GH-axis peptides and the beginning of compounding pharmacy interest in unapproved peptides. Sermorelin (GHRH 1–29), a growth hormone releasing hormone analog, was FDA-approved in 1997 for GH deficiency diagnosis and later for idiopathic GH deficiency treatment. However, Serono—the manufacturer—withdrew Sermorelin from commercial markets in 2002 after market economics made it unprofitable.

Sermorelin's withdrawal created the prototype for what would happen repeatedly with niche peptide medicines: once the commercial product was unavailable, compounding pharmacies began preparing it for patients who had previously been treated with it. The FDA's compounding framework—then less formalized than today—accommodated this. Sermorelin became one of the first peptides to migrate from the pharmaceutical market into widespread compounding pharmacy use, where it remains today.

The 1990s also saw the emergence of research peptides being sold directly to consumers in the US for the first time through early internet commerce. GHRP-2, GHRP-6, and Hexarelin—growth hormone releasing peptides discovered through academic research in the 1980s and 1990s—were among the first research peptides to circulate in fitness communities. Regulatory awareness of this market was essentially zero in the 1990s.

Regulatory lesson from this era: Commercial abandonment of approved peptides does not eliminate demand—it redirects it into compounding channels and eventually into unregulated markets.

2000s: The Internet Era and the Research Chemical Market

The 2000s transformed the research peptide market. Internet e-commerce enabled direct-to-consumer sales of research chemicals globally. Chinese chemical manufacturers, who had developed significant capacity for custom peptide synthesis as a result of the pharmaceutical industry outsourcing API production, became the primary global source for research peptides.

Compounds isolated in academic research in the 1980s and 1990s—BPC-157, thymosin beta-4, TB-500, thymosin alpha-1, and eventually Ipamorelin, CJC-1295, and modified GHRH analogs—became accessible to anyone with an internet connection and a credit card. The "research chemical" framing that would define the market for the next two decades emerged in this period, borrowed partly from the psychoactive research chemical market.

The FDA's enforcement capacity was not scaled to monitor the explosion of small parcel imports and domestic online vendors. The agency's enforcement posture through the mid-2000s was primarily reactive—responding to specific complaints, significant adverse events, or explicit fraud—rather than systematic.

Regulatory lesson from this era: Digital commerce and global supply chains allowed research peptides to proliferate far faster than regulatory frameworks could adapt.

2013: The DQSA and the Modern Compounding Framework

The Drug Quality and Security Act (DQSA) of 2013 was the most consequential piece of US legislation for the compounding pharmacy industry in decades. Passed in the aftermath of a 2012 fungal meningitis outbreak linked to contaminated compounded methylprednisolone from the New England Compounding Center (which killed 64 people), DQSA created the 503A/503B framework that governs compounded peptides today.

Key elements:

• 503A pharmacies (traditional prescription compounders) got clearer operating rules and state primacy retained
• 503B outsourcing facilities (large-scale compounders) were created as a new category subject to FDA cGMP oversight
• The bulk drug substance list process was formalized—a mechanism for the FDA to determine which substances could be used in compounding

DQSA gave the FDA the regulatory architecture to systematically evaluate which peptides could be compounded legally. It also created the Category 1/2/3 framework that has driven much of the peptide policy debate since 2015.

Regulatory lesson from this era: Regulatory frameworks often emerge from crises rather than foresight—and the peptide compounding framework was built on a foundation designed to prevent a pharmaceutical safety disaster rather than to coherently regulate a therapeutic peptide market.

2015–2022: FDA Begins BDS Reviews, Market Grows

The FDA began systematically reviewing bulk drug substance nominations in the mid-2010s. Nominations came from compounding pharmacies, physician groups, patient advocates, and researchers. The review process was slower than anticipated—dozens of substances remained in Category 3 (under evaluation) for years.

During this same period, the research peptide market expanded dramatically. GHRP and GHRH analogs, BPC-157, TB-500, selank, semax, thymosin compounds, and later peptides like Epithalon/Epitalon and SS-31 circulated widely through research chemical vendors. The anti-aging, biohacking, and performance communities drove demand. Podcasts, YouTube channels, and social media amplified awareness.

The FDA issued scattered warning letters to vendors making egregious health claims but did not systematically address the research peptide market. The agency's attention was focused elsewhere (opioid crisis, biosimilar policy, rare disease drugs), and the peptide market's health risk profile—while uncertain—was not generating the acute fatality signals that typically drive enforcement escalation.

Regulatory lesson from this era: Market growth outpaced enforcement capacity; the gap between legal pharmaceutical peptides and unregulated research compounds widened rather than narrowed.

2023–2025: Enforcement Escalation

The period from 2023 to 2025 saw the most significant enforcement activity against the research peptide market since the FDA had any awareness of it:

• The FDA issued warning letters to multiple US research peptide vendors
• BPC-157 BDS review created uncertainty in the compounding market
• Australia conducted its most aggressive enforcement operation against domestic peptide vendors
• WADA added BPC-157 to its Prohibited List in 2023
• The semaglutide compounding controversy focused Congressional and media attention on compounding pharmacy regulation broadly
• Several major US research peptide vendors ceased operations or restructured

Simultaneously, mainstream medical adoption of peptide therapy—particularly GLP-1 agonists for obesity—dramatically increased public and regulatory awareness of peptides generally.

2026: The Current Landscape and Future Outlook

As of 2026, the regulatory landscape reflects the accumulated effects of this history:

• FDA-approved peptide drugs are a large and growing category (GLP-1s dominating the market)
• The compounding pharmacy pathway for unapproved peptides is functional but under increasing scrutiny
• The research chemical market is substantially more constrained than in 2020 but has not been eliminated
• International enforcement variation remains significant, with Australia strictest and developing countries most permissive

Future trends: The regulatory direction is clearly toward tighter oversight rather than looser. The questions are pace and specificity: how quickly will the FDA finalize BDS determinations, what enforcement resources will be allocated to the research chemical market, and will Congress legislate new frameworks for the research peptide category? The long-term trajectory almost certainly includes more—not fewer—peptides moving into formal prescription pathways as clinical evidence accumulates and commercial interest develops.

Frequently Asked Questions

Q: Why aren't most research peptides FDA-approved? FDA drug approval is expensive (hundreds of millions to billions of dollars) and requires clinical trial data demonstrating safety and efficacy for a specific indication in a specific population. Most research peptides have not attracted pharmaceutical company investment sufficient to fund this process because the commercial opportunity is unclear. Patent protection on many research peptides has expired or is unavailable, reducing the commercial incentive.

Q: What caused the current regulatory crackdown on research peptides? Several factors converged: market growth made the unregulated peptide market too large to ignore; high-profile safety concerns with some compounds attracted adverse attention; the semaglutide shortage controversy raised the profile of compounding pharmacy regulation broadly; and natural institutional lifecycle—regulatory awareness catches up with market realities eventually.

Q: Will BPC-157 eventually get FDA approval? Possibly. BPC-157 has a substantial preclinical research base but limited human clinical trial data. A pharmaceutical company or academic consortium would need to invest in clinical trials for a specific indication. Research into BPC-157's potential for inflammatory bowel disease or wound healing could provide a path, but commercial timelines for this kind of development are measured in decades.

Q: How did insulin avoid being a research chemical? Insulin was discovered at a time when pharmaceutical companies immediately recognized its commercial potential, invested in large-scale manufacturing, and navigated the (then simpler) regulatory framework. It became a regulated pharmaceutical product before there was any meaningful concept of a research chemical market. Timing was everything.

Q: What is the most likely near-term regulatory change affecting peptides? FDA finalization of BDS list determinations—particularly for BPC-157—is the most consequential near-term regulatory action for the US prescription peptide market. A Category 2 determination for BPC-157 would eliminate it from the compounding pharmacy pathway; a Category 1 determination would secure it. See FDA Peptide Regulations 2026 Update for the current status.

Related Articles

• FDA Peptide Regulations 2026 Update
• Are Peptides Legal? Complete US and International Guide
• Peptide Legal Status in the US
• Future of Peptide Therapy
• FDA Approved Peptides

Track your health protocols and biomarkers over time in Optimize.